articleThe Lancet OncologySep 14, 2015Closed access

Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial

Cardiff University · Nottingham University Hospitals NHS Trust · +11 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

540
total citations
FWCI
23.04
Percentile
100%
References
34
Citations per year

Authors

16

Topics & keywords

Keywords
  • Arsenic trioxide
  • Idarubicin
  • Medicine
  • Acute promyelocytic leukemia
  • Internal medicine
  • Regimen
  • Chemotherapy
  • Gastroenterology
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding